s CTN Dissemination Library: Protocol CTN-0051 - Extended-Release Naltrexone

  PROTOCOL NIDA-CTN-0051


Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)

John Rotrosen, MD
Lead Investigator

New York University School of Medicine
john.rotrosen@nyumc.org

This study will assess the comparative effectiveness of extended release injectable naltrexone (XR-NTX, Vivitrol®) versus buprenorphine-naloxone (BUP-NX, Suboxone®) as pharmacotherapeutic aids to recovery amongst treatment-seeking participants who have completed detoxification and achieved short term abstinence. The primary objective is to compare the effectiveness of XR-NTX versus BUP-NX in promoting the joint outcome of sustained retention in treatment and abstinence after an index admission for opioid dependence. A rescue protocol will enable the study to address additional questions regarding the sequencing of treatments.

RELATED STUDIES
RELATED RESOURCES

snowflake

Publications about CTN-0051

ClinicalTrials.gov (NCT02032433)

NIDA protocol page


NODES & CTPs SEARCH LINK
Greater New York (Lead) search www
  Bellevue Hospital Center search www
Mid-Atlantic search www
  Avery Road Treatment Center search www
Florida Node Alliance search www
Gateway Community Services search www
New England Consortium search www
SSTAR of Massachusetts search www
Ohio Valley search www
Maryhaven, Inc. search www
Pacific Northwest search www
  Evergreen Treatment Services search www
Pacific Region search www
Tarzana Treatment Center search www
Southwest search www
Turquoise Lodge Hospital search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 11/2016 -- http://ctndisseminationlibrary.org/protocols/ctn0051.htm
info@ctndisseminationlibrary.org